Last €5.62 EUR
Change Today +0.044 / 0.79%
Volume 6.1K
APS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 9:34 AM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (APS) Snapshot

Open
€5.77
Previous Close
€5.57
Day High
€5.77
Day Low
€5.56
52 Week High
01/27/14 - €7.31
52 Week Low
07/18/14 - €3.62
Market Cap
1.1B
Average Volume 10 Days
8.2K
EPS TTM
--
Shares Outstanding
187.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARIAD PHARMACEUTICALS INC (APS)

ariad pharmaceuticals inc (APS) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (APS) Details

ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

307 Employees
Last Reported Date: 03/3/14
Founded in 1991

ariad pharmaceuticals inc (APS) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $749.8K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $465.4K
President of Research & Development and Chief...
Total Annual Compensation: $492.4K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $427.3K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $386.4K
Compensation as of Fiscal Year 2013.

ariad pharmaceuticals inc (APS) Key Developments

ARIAD Pharmaceuticals Appoints Thomas J. Desrosier as Executive Vice President, Chief Legal and Administration Officer, and Secretary

ARIAD Pharmaceuticals Inc. announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to ARIADâ s chairman and chief executive officer, Harvey J. Berger, M.D. Mr. DesRosier has more than 30 years of global biotechnology and pharmaceutical industry experience and joins ARIAD from Cubist Pharmaceuticals Inc., where he held the same position as the one he will assume at ARIAD.

ARIAD Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2018; Re-Affirms Earnings Guidance for the Year 2014

ARIAD Pharmaceuticals Inc. provided earnings guidance for the year 2018. The company expects to achieve profitability in 2018 through revenue growth and strategic partnerships over the next three years. This includes Iclusig revenue growth in the U.S. and in Europe, as well as Iclusig revenue from Japan and new geographies. The company also anticipates increased cash flow from brigatinib revenue and partnership payments during this time period. Based on the plan, the company expects to achieve sustained profitability based on more than $400 million in anticipated product revenue in 2018. The company re-affirmed earnings guidance for the year 2014. For the year 2014, the company expects revenues of $580 million to $600 million. Adjusted earnings per share are to be in the range of $3.23 to $3.47.

ARIAD Pharmaceuticals Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015

ARIAD Pharmaceuticals Inc. announced that it has concluded consultations with U.S. and European health authorities regarding the design of a randomized, dose-ranging trial to evaluate three starting doses of Iclusig (ponatinib) in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML). The trial is expected to inform the optimal use of Iclusig in these patients and will begin by mid-2015. Approximately 450 patients will be enrolled at clinical sites around the world. This clinical trial is expected to provide important data regarding the efficacy of Iclusig treatment initiating at doses less than the currently approved starting dose and maintaining patients on a lower dose. This study will enroll patients with CP-CML who are resistant to at least two approved tyrosine kinase inhibitors. These patients will be randomized equally to receive once-daily administration of 45 mg (cohort A), 30 mg (cohort B) or 15 mg (cohort C) of Iclusig. Patients in cohorts A and B will have their daily dose reduced to 15 mg upon achievement of major cytogenetic response (MCyR). The primary endpoint of the trial is MCyR by 12 months for each cohort. Secondary endpoints include rate of vascular occlusive events in each dose cohort, rates of adverse events and rates of serious adverse events. Other secondary endpoints include cytogenetic, molecular and hematologic response rates, tolerability, duration of response, time to response, disease control rate, progression-free survival and overall survival.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APS:GR €5.62 EUR +0.044

APS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.60 USD -0.02
Array BioPharma Inc $7.54 USD -0.2649
Evotec AG €3.66 EUR -0.057
Infinity Pharmaceuticals Inc $15.83 USD +0.03
Progenics Pharmaceuticals Inc $6.32 USD -0.04
View Industry Companies
 

Industry Analysis

APS

Industry Average

Valuation APS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.3x
Price/Book 14.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit www.ariad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.